Criterion	Inclusion	Exclusion
Study design	For diagnostic and staging reviews Any study for which a 2×2 contingency table can be extracted, e.g. diagnostic case control studies 'cross‐sectional' test accuracy study with retrospective or prospective data collection studies where estimation of test accuracy was not the primary objective but test results for both index and reference standard were available RCTs of tests or testing strategies where participants were randomised between index tests and all undergo a reference standard (i.e. accuracy RCTs)	< 5 melanoma cases (diagnosis reviews) < 10 participants (staging reviews) Studies developing new criteria for diagnosis unless a separate 'test set' of images were used to evaluate the criteria (mainly digital dermoscopy) Studies using 'normal' skin as controls Letters, editorials, comment papers, narrative reviews Insufficient data to construct a 2×2 table
Target condition	Melanoma Keratinocyte skin cancer (or non‐melanoma skin cancer) BCC or epithelioma cSCC	Studies exclusively conducted in children Studies of non‐cutaneous melanoma or SCC
Population	For diagnostic reviews Adults with a skin lesion suspicious for melanoma, BCC, or cSCC (other terms include pigmented skin lesion/nevi, melanocytic, keratinocyte, etc.) Adults at high risk of developing melanoma skin cancer, BCC, or cSCC For staging reviews Adults with a diagnosis of melanoma or cSCC undergoing tests for staging of lymph nodes or distant metastases or both	People suspected of other forms of skin cancer Studies conducted exclusively in children
Index tests	For diagnosis Visual inspection/clinical examination Dermoscopy/dermatoscopy Teledermoscpoy Smartphone/mobile phone applications Digital dermoscopy/artificial intelligence Confocal microscopy Ocular coherence tomography Exfoliative cytology High‐frequency ultrasound Canine odour detection DNA expression analysis/gene chip analysis Other For staging CT PET PET‐CT MRI Ultrasound +/fine needle aspiration cytology FNAC SLNB +/high‐frequency ultrasound Other Any test combination and in any order Any test positivity threshold Any variation in testing procedure (e.g. radioisotope used)	Sentinel lymph biopsy for therapeutic rather than staging purposes Tests to determine melanoma thickness Tests to determine surgical margins/lesion borders Tests to improve histopathology diagnose LND
Reference standard	For diagnostic studies Histopathology of the excised lesion Clinical follow‐up of non‐excised/benign appearing lesions with later histopathology if suspicious Expert diagnosis (studies should not be included if expert diagnosis is the sole reference standard) For studies of imaging tests for staging Histopathology (via LND or SLMB) Clinical/radiological follow‐up A combination of the above For studies of SLNB accuracy for staging LND of both SLN+ and SLn participants to identify all diseased nodes LND of SLN+ participants and follow‐up of SLN participants to identify a subsequent nodal recurrence in a previously investigated nodal basin	For diagnostic studies Exclude if any disease positive participants have diagnosis unconfirmed by histology Exclude if > 50% of disease negative participants have diagnosis confirmed by expert opinion with no histology or follow‐up Exclude studies of referral accuracy, i.e. comparing referral decision with expert diagnosis, unless evaluations of teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET‐CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.